论文部分内容阅读
在冠状动脉病的治疗中,吗多明为一有效益药物。在慕尼黑(1978)、莫斯科(1980)及罗塔赫-埃格尔(1982)的国际讨论会曾介绍其实验室研究及临床应用的基本情况。该药适用于治疗心绞痛,且能增加对运动的耐受量,使心绞痛明显减轻或消失,基本上无副作用,且无耐药性。由于时间的限制,在议程Ⅲ至Ⅵ中仅提到一些主要的临床结果,其他例如对血小板聚集及心肌保护作用的讨论亦表明本药较
In the treatment of coronary artery disease, you doomed as an effective drug. The international seminars in Munich (1978), Moscow (1980) and Rottach-Eger (1982) introduced basic facts about their laboratory research and clinical applications. The drug is suitable for the treatment of angina pectoris, and can increase the amount of exercise tolerance, angina significantly reduced or disappeared, basically no side effects, and no resistance. Due to time constraints, only a few major clinical outcomes are mentioned in Agenda III to VI, and other discussions such as platelet aggregation and cardioprotection also suggest that this drug is more